Leerink Partnrs Analysts Cut Earnings Estimates for MannKind

MannKind Corporation (NASDAQ:MNKD) – Equities researchers at Leerink Partnrs reduced their FY2026 earnings per share (EPS) estimates for shares of MannKind in a note issued to investors on Wednesday, June 18th. Leerink Partnrs analyst F. Khurshid now expects that the biopharmaceutical company will earn $0.14 per share for the year, down from their prior estimate of $0.16. The consensus estimate for MannKind’s current full-year earnings is $0.10 per share.

MNKD has been the topic of several other reports. Wall Street Zen upgraded MannKind from a “hold” rating to a “buy” rating in a research report on Saturday, June 14th. Mizuho began coverage on MannKind in a research report on Thursday, April 10th. They issued an “outperform” rating and a $12.00 target price on the stock. Finally, Wedbush restated an “outperform” rating and issued a $11.00 target price on shares of MannKind in a research report on Thursday, February 27th. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $10.33.

MannKind Trading Down 1.0%

Shares of MannKind stock opened at $3.77 on Thursday. The business’s 50 day simple moving average is $4.40 and its 200-day simple moving average is $5.27. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of 37.70 and a beta of 1.02. MannKind has a twelve month low of $3.63 and a twelve month high of $7.63.

MannKind (NASDAQ:MNKD) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.01. The business had revenue of $78.35 million for the quarter, compared to analysts’ expectations of $75.86 million. MannKind had a negative return on equity of 32.41% and a net margin of 10.12%. The business’s quarterly revenue was up 18.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.05 EPS.

Insider Activity

In other news, Director Steven B. Binder sold 80,144 shares of MannKind stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $4.69, for a total transaction of $375,875.36. Following the transaction, the director now directly owns 1,006,611 shares in the company, valued at approximately $4,721,005.59. This trade represents a 7.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP David Thomson sold 32,179 shares of MannKind stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $4.68, for a total value of $150,597.72. Following the transaction, the executive vice president now owns 772,427 shares in the company, valued at approximately $3,614,958.36. This trade represents a 4.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 190,831 shares of company stock worth $846,298. 2.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On MannKind

Hedge funds have recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new position in shares of MannKind during the 4th quarter valued at $37,000. Jones Financial Companies Lllp increased its position in shares of MannKind by 3,294.8% during the 4th quarter. Jones Financial Companies Lllp now owns 6,586 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 6,392 shares during the period. Kovitz Investment Group Partners LLC acquired a new position in shares of MannKind during the 4th quarter valued at $65,000. Blueshift Asset Management LLC acquired a new position in shares of MannKind during the 1st quarter valued at $51,000. Finally, Beirne Wealth Consulting Services LLC bought a new stake in shares of MannKind during the 4th quarter worth $66,000. 49.55% of the stock is currently owned by institutional investors and hedge funds.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.